Vigonvita Life Sciences Co Ltd

02630

Company Profile

  • Business description

    Vigonvita Life Sciences Co Ltd biopharmaceutical company. It is focused on innovation driven biopharmaceutical development, with a strategic emphasis on addressing unmet clinical needs in the treatment of neuropsychiatric, infectious, and andrological diseases. The company's core Products include LV232, anti-depression drug candidate, VV913: a novel investigational drug candidate for premature ejaculation and, VV116: an oral nucleoside analog with broad-spectrum antiviral potential. The company's operations are located in the PRC and Uzbekistan. Revenue is generated from the out-licensing and the sales of its pharmaceutical products.

  • Contact

    No. 108, Yuxin Road
    8th Floor, Building A
    Suzhou Industrial Park District
    Suzhou215123
    CHN

    T: +86 51262898861

    https://www.vigonvita.cn

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2026

    Employees

    315

Stocks News & Analysis

stocks

Cheap ASX share may have more room to run

Shares are cheap despite rebounding share price, yet risks remain.
stocks

ASX listed media giant drives strong earnings growth

Digital growth drives earnings beat for media share.
stocks

ASX real estate platform outperforms yet questions remain

Valuation remains a key concern despite strong August reporting.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,424.1013.30-0.14%
CAC 408,715.320.390.00%
DAX 4026,357.5738.120.14%
Dow JONES (US)54,036.93151.830.28%
FTSE 10010,886.6814.41-0.13%
HKSE25,902.16234.130.91%
NASDAQ26,690.62342.261.30%
Nikkei 22566,970.221,363.512.08%
NZX 50 Index13,888.2464.110.46%
S&P 5007,757.6447.680.62%
S&P/ASX 2009,232.6017.00-0.18%
SSE Composite Index3,966.5926.560.67%

Market Movers